drugset / Trial / NCT05378698

Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation

NCT05378698

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood. A better understanding of the mechanisms underlying the clinical effects of tralokinumab would be of great clinical benefit since it may ultimately help us to identify more precisely candidate patients who may benefit from a therapy with tralokinumab.

Timeline

Start
2022-06-15
Primary completion
2025-03-04
Completion
2025-03-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tralokinumab Monoclonal antibody

Indications